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ABSTRACT 
 
 
This simple quantitative research investigated whether patients with cancer 
developed depression whilst receiving adjuvant chemotherapy, and whether 
there was a particular time in the treatment cycle that it was likely to 
develop.  A longitudinal survey method was chosen and the instrument of 
use was the Beck Depression Inventory II (BDI-II).   The content of this 
survey include factors that reflect negative attitudes towards self, 
performance impairment and somatic disturbances as well as general 
factors of depression.   
 
Twenty-six participants were given the BDI-II, and asked to report on side 
effects that they had experienced every two weeks whilst they were 
receiving chemotherapy. The study took place in two regional oncology 
clinics. 
 
This report demonstrates that, patients can develop depression whilst 
receiving adjuvant chemotherapy.  The study revealed that the 5th fortnight 
into a patient’s chemotherapy treatment was a more vulnerable point in their 
treatment to develop depression. 
 
        Descriptive analysis illustrated that more females than males suffered 
depression and that those receiving treatment for breast cancer were more 
likely to develop depression. 
 
Correlation statistics demonstrated a relationship between fatigue and 
depressive symptoms. There was no statistically significant correlation 
between the number of side effects experienced by participants and 
depression. 
 
In summary, the findings suggest that patients were more vulnerable to 
developing depression around the 5th fortnight of their chemotherapy cycle.  
This research has demonstrated throughout that depression does occur in 
patients receiving adjuvant chemotherapy and that female patients are 
more likely to develop depression than males.  
 
Due to the small sample size though, the results were not statistically 
significant. The findings from this research could provide direction for more 
thorough studies in the future. 
 
The style of reporting used throughout this thesis has been the Harvard 
referencing style to ensure compliance with the university requirements and 
to maintain consistency. 
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CHAPTER  1:  INTRODUCTION 
This thesis reports on an investigation of whether there is a key point when 
patients receiving adjuvant chemotherapy are more likely to develop depression 
within their treatment cycle. The study was based on a simple survey method 
using the Beck Depression Inventory. The first chapter of the thesis presents the 
background to the study, identifies the research problem and describes its 
significance. The chapter concludes by noting the limitations of the study and 
some key assumptions.  
 
Research Background 
Although cancer treatment has undergone an evolution of treatment modalities, 
the emotional impact on sufferers remains high. The developments in surgery, 
chemotherapy and radiotherapy mean that the survival rate of people diagnosed 
with cancer has increased (Bottomley, 1997; Paraska, & Bender, 2003). 
Adjuvant chemotherapy is chemotherapy that is given after surgical removal of 
the primary tumour where there is known to be a high risk of future tumour 
recurrence arising from micro metastases (Varricchio, 1997).   The common side 
effects of adjuvant chemotherapy are nausea and vomiting, impaired bowel 
function (including diarrhoea or constipation), mucositis, alopecia, 
thrombocytopenia, anaemia, neutropenia, anorexia and peripheral neuropathy 
(Varricchio, 1997). There has been a lot of research on the debilitating physical 
and psychological effects that coincide with a diagnosis of cancer. Patients with 
psychological issues can have more severe physical side effects; they could be 
less compliant with the course of the treatment, and cause a greater strain on 
the health care system (Pascoe, Endelman, & Kidman, 2000).   
 
A study conducted by Macmillan Cancer Support between December 2005 and 
February 2006 reported that the emotional aspects of a cancer diagnosis are the 
most difficult effects to deal with. The authors reported that 58% of participants 
agreed with the statement that “your emotional needs are not looked after as 
much as your physical needs” (Cardy et al 2006 p 11).   Unfortunately, there is 
also little support for the reported emotional aspects related to a cancer 
diagnosis. For example, 60% of patients who experienced depression did not 
receive any information, advice, support or treatment (Cardy et al 2006).  In this 
same study, depression remained an important factor related to cancer and its 
treatment yet research showed it is still misdiagnosed, inadequately treated or 
not treated at all (Cardy et al 2006).  Depression describes “a spectrum of mood 
disturbances ranging from mild to severe and from transient to persistent” 
(Peveler, Carson, Rodin, 2002 p 149). The diagnosis depends on the presence 
of two cardinal symptoms including, a) persistent and pervasive low mood and 
b) loss of interest or pleasure in usual activities (Peveler et al 2002).  
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A focal issue in the research surrounding depression and chemotherapy has 
been the impact that the oncology nurse has on a patient’s treatment outcome. 
Oncology nurses work as part of a team with other cancer care providers and 
allied health staff. Their daily activities include caring for patients diagnosed with 
cancer, offering education and support to patients and their families, 
administering chemotherapy or other treatments, managing chemotherapy side 
effects and assessing their patients ongoing needs and educational deficits. 
Oncology nurses often have an intimate role in assisting patients 
psychologically, physically and emotionally. Nurses in oncology recognise the 
potential for discovering and giving. It is evident that, in providing for the unique 
needs of cancer patients and their family, a broad variety of experiences and 
feelings can be encountered ranging from extremely stressful to extremely 
rewarding and from extremely sad to extremely fulfilling. The people who choose 
to work in this field are usually passionate about their work. The oncology nurse 
is challenged by the fact that every patient is different, every cancer is different 
and the course of every illness is different from every other. Now, more than 
ever, with all the changes in cancer care, compassion, competence and 
conscientious nursing care is a basic right of cancer patients and their families. It 
is evident that professionals working with cancer patients will need the 
necessary knowledge and skills to acknowledge and explore patient’s feeling if 
they want to be able to give them the reassurance and care they need (Rooyen, 
Roux, Kotze 2008).  
 
A number of researchers (McDonald et al 1999 and Zhao et al 2003) suggested 
a need for nurses to understand and implement interventions for patients 
experiencing psychological effects during chemotherapy treatment.  McDonald 
et al (1999) reported that nurses’ assessment of their patient’s psychological 
state underestimated the level of depression they were actually experiencing. 
Their conclusion was to improve the nurse’s assessment by placing a greater 
emphasis on using screening tools and incorporating them into nursing practice, 
as an alternative to relying on the nurse’s judgement alone. 
 
Research Objectives 
 
The aim of this study was to identify a time frame in which patients are more 
vulnerable to developing depression. The research questions are:  
1) Is there a particular point within the chemotherapy treatment cycle that 
patients are vulnerable to developing depression?  
2) Is there a relationship between the number of side effects experienced by 
patients receiving adjuvant chemotherapy and depression?  
3) What is the relationship between depressive symptoms, patient 
characteristics and side effects? 
 
 - 2 - 
Justification 
This research is of national significance due to the high incidence of cancer and 
depression. There are more than 85,000 new cases of cancer diagnosed in 
Australia each year (Cancer Council Australia 2003).  Depression also 
represents a common diagnosis with one million Australian adults and 100,000 
young people living with depression each year. On average, one in five people 
will experience depression in their lives; one in four females and one in six 
males (Beyond Blue: The National Depression Initiative 2005). In a pilot study by 
Strong, Sharpe, Cull, Maguire, House & Ramirez, (2003) and another study by 
Love, Grabsch, Clarke, Bloch, Kissane, (2004), the prevalence of depression in 
cancer patients was up to 50%.  Pascoe et al (2000) also reported that there 
were a substantial proportion of patients who were diagnosed with cancer that 
experienced anxiety and depression, but they have not provided figures for this.  
 
Anecdotal evidence has revealed that depression does occur in patients who 
receive adjuvant chemotherapy yet there is little published literature based on 
the investigation of whether there is a point in the treatment process when they 
are most vulnerable.  This study addressed the issue of time being an important 
factor in a patient’s cycle of chemotherapy. The purpose of this study was also 
to produce research that could later be expanded on to further address this 
issue.  
 
The final rationale for this study was to produce research which could be used to 
educate oncology nurses to create an awareness of psychological side effects in 
chemotherapy patients. 
 
Limitations 
 
Limitations of the study included a small sample size and potential biases due to 
self-selection of the candidates and their self-evaluation of their experiences. 
The limitation of self-selection bias is intrinsic in any study that uses volunteers.  
Patients that volunteered to participate in this study were provided with an 
information sheet which outlined the benefits of the study and consent was 
obtained. The patients were particularly vulnerable as they were facing a 
traumatic life event of being diagnosed with cancer and undergoing 
chemotherapy. This vulnerability could mean that they were less likely to 
participate in any outside projects. 
 
The sample size of the study limits the ability to produce statistically significant 
results. Despite this lack of statistical significance, this study is important as an 
indication of the presence and timing of depression in this sample of people, 
suggesting that it is an important area for further research. Information bias 
should also be considered in this study as a limitation, as the study relied upon 
the patients reporting their experiences honestly.  
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CHAPTER  2: LITERATURE  REVIEW 
The following literature review is structured into a format using subheadings to 
indicate the themes found in the literature search. The structure of the literature 
review is as follows: 
 
1. Literature Search Strategies 
2. Initial Overview: A general discussion on depression 
3. Depression and Cancer 
4. Depression and Breast Cancer 
5. Depression and Adjuvant Chemotherapy 
6. Depression and Oncology Nurses 
7. Depression Assessment Tools used in Cancer Research 
 
This format has been used to best direct discussion regarding each issue. The 
search strategies used for the literature review are outlined. The main central 
theme, depression, is then discussed in the initial overview to provide the reader 
with background information on the illness that is being monitored in the study.  
What follows is an outline of each variable presented as a discussion in relation 
to depression. The variables are broken down to provide the reader with an 
overview of each issue and then constructed to highlight the variances or 
similarities in the literature found. The section on depression and cancer 
illustrates the prevalence of psychological issues that come with the diagnosis of 
cancer alone without the impact of any treatments.  Depression and breast 
cancer is a chapter on its own due to the fact that there was so much more 
literature found on this topic than any other cancer. Depression and adjuvant 
chemotherapy highlighted the studies already performed looking specifically at 
these two variables and provides the researcher with a basis on which to 
compare and contrast. Literature on depression and oncology nurses was 
included as one of the purposes behind the study was to increase awareness of 
oncology nurses that their patients do suffer from depression so it was 
significant to see what the current studies are saying that nurses are 
experiencing. Finally, depression and assessment tools used in cancer research 
were also investigated to provide the researcher with the knowledge to 
determine which would be the most appropriate to use in this research.  
 
Literature Search Strategies 
The search for literature on the topic of depression in patients with cancer 
receiving adjuvant chemotherapy began in 2003. It started by exploring all 
databases available that contained nursing and psychological journals. These 
databases included CINAHL with full text; Wiley InterScience; PsychINFO and 
PsychARTICLES; ProQuest; Blackwell Synergy; Aus Stats. The literature search 
was then extended to look more intricately at research surrounding the topic, for 
example, oncology nurses and the side effects of adjuvant chemotherapy. The 
following databases were later explored while still searching the previous 
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databases; EBSCOhost MegaFile Premier; CINAHL with full text on the 
EBSCOhost Platform; Johanna Briggs Institute. The search terms used 
included, depression, adjuvant and chemotherapy, cancer, oncology nurses. 
 
INITIAL  OVERVIEW:  Depression 
Depression has proved to be costly both in terms of morbidity and in terms of 
financial expense.  The Beyond Blue (2007) web site reports that depression 
“costs the Australian community $600 million dollars each year”.  Peveler et al 
(2002), discussed depression as a major health problem.  In their paper, The 
World Health Organisation is cited as predicting that depression will be “one of 
the two most prominent causes of disability in the world by 2020” (Peveler et al 
2002 p149).   A ‘Google’ search in 2007 on depression, revealed 88 800 000 
sites thus evidence of its growing importance in the world community. 
 
Depression is generally a mood state characterized by feelings of emptiness, of 
not being your usual self; having low self esteem and no self confidence 
(Mondimore 2006). Signs of a depressed mood include; low self esteem or self 
worth; change in sleep patterns; changes to appetite or weight; a reduced 
capacity to experience pleasure; reduced ability to control emotions; difficulty in 
being affectionate; poor concentration or memory; reduced motivation; lowered 
energy levels; tearfulness and crying; avoiding social contact and generalized 
negativity and pessimism (Mondimore 2006). 
 
Diagnosing depression in people who are medically ill can be complicated. The 
standard way of assessing depression includes the use of screening tools that 
explore behavioural, cognitive and physical aspects; such as loss of interest and 
fatigue. The physical aspects of depression are also common symptoms of a 
medical illness. Peveler, Carson and Rodin, (2002) like many other authors, 
such as Strong et al. (2003) and Love et al (2004) agree that depression is not 
detected or adequately treated, particularly when it coexists with a medical 
illness. Alternatively, the Black Dog Institute (2007) have stated that there is a 
risk of non-depressed people being falsely diagnosed with depression because 
of the physical aspects that are associated with it.   
 
Depression and Cancer 
The relationship between cancer and depression is complex and for the 
purposes of this study the focus will be on the medical framework when looking 
at the link between depression and cancer. A diagnosis of cancer is one of life’s 
most disturbing and dispiriting events bringing with it psychological distress, 
physical suffering and the possibility of a foreshortened future. Society’s fear of 
cancer promotes the assumption that depression is understandable and a 
normal reaction to the disease.  
Diagnosing depression in the context of cancer is complicated by the overlap of 
depressive and sickness symptoms, as well as by the question of whether 
 - 5 - 
depression should be viewed as a categoric disorder or a spectrum condition 
(Raison and Miller 2003).  Historically, the research surrounding depression and 
cancer has been along two paths, cause (depression is a risk factor for cancer 
and cancer progression) and consequence (depression as an effect of cancer 
diagnosis and treatment) (Croyle and Rowland 2003) More recently there has 
been research developments in the potential that behavioural alterations in 
cancer patients may be a result from the activation of the inflammatory cytokine 
network (Raison et al 2003).  This research into cytokines provides tentative 
evidence that cancer cells in our bodies might trigger changes in our brains. It 
might turn out that feeling depressed about a diagnosis of cancer or dreading 
the next round of chemotherapy isn’t one’s own fault or weakness, but a 
treatable medical condition caused by the cancer cells releasing chemicals into 
your body (Raison et al 2003).  
 
The National Cancer Institute (2008) reports more recent figures of 15-25% of 
cancer patients are affected by depression. Some of the important issues that 
people are faced with when diagnosed with depression include, fear of death, 
interruption in life plans, changes in body image or self esteem, changes in 
social role and lifestyle, money and legal concerns. People who are diagnosed 
with depression will react to these things in different ways and may not 
experience serious depression and anxiety. There are many misconceptions 
about cancer and how people cope with it such as, all people with cancer are 
depressed and this is normal, treatment does not help their depression and 
everyone with cancer faces a painful death (National Cancer Institute 2008). 
Cancer related depression is not substantially different from depression in other 
illnesses but treatments may need to be adapted or refined for cancer patients. 
Depression is under diagnosed in the general population, not just cancer 
patients. For example, a cancer patient might be experiencing depression at a 
level which would equate to diagnostic criteria for a depressive episode. This 
episode might be considered mild or a subclinical level of depression in 
someone in the general population (National Cancer Institute 2008).  
 
Maguire (1994) investigated symptoms experienced by women with breast 
cancer who require a medical intervention to prevent clinical depression or 
anxiety.  This study revealed that nearly 30% of women with breast cancer may 
experience anxiety or depression within a year of diagnosis, and that psychiatric 
morbidity increases further when the patient receives radiotherapy or 
chemotherapy.   
 
Bottomley et al (1997) performed a literature review on the psychological 
problems of cancer patients.  The degrees of psychological problems were 
attributed to a number of things including the type of surgery the patient had 
undergone. Bottomley et al (1997) reported that patients receiving a mastectomy 
had more problems with sexual issues, body image, low self esteem, anxiety 
and depression than someone having a melanoma removed. There was also an 
association between the type of chemotherapy the patient received, such as 
alkaline and vinca alkaloids (vincristine) and depression. The author found that 
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cognitive assessment was important and that 54% of the most serious side 
effects on women with breast cancer when undergoing chemotherapy were 
psychologically manifested (Bottomley et al 1997).  Scott, (1991) as cited in 
Bottomley et al (1997) found the use of corticosteroids, such as 
Dexamethasone, can also lead to mood disorders of increased depression.  In 
the Bottomley et al (1997) literature review it was concluded that depression was 
common with a cancer diagnosis. Other factors that were associated with the 
risk of depression were; history of depression (Bottomley et al 1997 and Peveler 
et al 2002) marital status, education, stage of disease at diagnosis, and 
treatment (Molassiotis et al 1996 and Maguire et al 1994). Depression can also 
occur at various levels depending on the type of cancer the patient has. For 
example, the level of depression in breast cancer patients is anywhere from 5-
48% according to Derogatis, Morrow and Fetting (1983), or 20-30% according to 
Silberfarb, Philbert & Levine (1987). More recent data by Burgess et al (2005) 
stated that nearly 50% of women with early breast cancer had depression or 
anxiety. Lung cancer patients also demonstrate varying levels of depression 
which could be linked to the physical difficulties that they experience, for 
example shortness of breath and limited physical exertion (Anderson, Lamb 
1992 as cited in Bottomley et al 1997). Early in 2006, the Macmillan Cancer 
Support published a report presenting the findings of a major quantitative survey 
conducted in the United Kingdom. The study explored the impact of a cancer 
diagnosis on the people affected by cancer, both those who received the 
diagnosis and their families and friends (Cardy et al 2006). The aim of the 
research was to establish any differences between the views and experiences of 
people affected by cancer and those who had never been affected by the 
disease (Cardy et al 2006). A total of 1,751 people took part in the survey, 
conducted between December 2005 and February 2006. The results showed 
that 49% of respondents experienced depression as a result of their cancer 
diagnosis and 60% said that they did not receive information, advice, support or 
treatment for this (Cardy et al 2006).   
 
Raison et al (2003) suggests that depression predisposes toward a worsened 
clinical outcome once cancer has developed. Stommel (2002) as cited in Raison 
et al (2003) has reported that patients with a history of depressive symptoms are 
at 2.6 times increased risk of dying from their cancer within the first 19 months 
after diagnosis.  Raison et al includes other factors that a diagnosis of 
depression will impact on. These include compliance with treatment, length of 
hospital stays, diminished quality of life and ability to care for oneself.  Cancer 
Research UK (2009) support the findings that depressive symptomology was the 
most consistent psychological predictor of shortened survival time.  
 
After reviewing the literature for this study which has covered research from at 
least 1990 to 2009, all papers report to some degree, that depression occurs in 
cancer patients. Despite the international recognition of depression in people 
with cancer over the last 17 years, the Macmillan study still reported staggering 
statistics like those mentioned above.  
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This demonstrates the need for improved interventions by health care 
professionals to address psychological issues in cancer care. Bottomley et al 
1997 stated that nurses need to undertake a more specialist role to improve the 
level of care for common psychological problems in cancer sufferers. This idea 
was supported by other researchers such as McDonald et al (1999) and Strong 
et al (2003). 
 
Depression and Breast Cancer 
Within the literature exploring depression and cancer, research designed 
specifically for patients with breast cancer was the most prevalent. Spagnola et 
al (2003 p463) explored the issues involved with a diagnosis of breast cancer 
and stated that it “continues to generate fear and turmoil”. Their study 
highlighted that quality of life can be negatively affected by inadequate 
information, complex decisions and adverse events related to cancer treatment.  
In a study involving 153 breast cancer patients from two oncology outpatient 
departments, one of the instruments used was the Satisfaction with Life 
Domains Scale for Breast Cancer (SLDA-BC). This tool was used to assess the 
patient’s quality of life throughout the various phases of care. The Functional 
Assessment of Cancer Therapy (FACT-B) was also used as it is specific for 
breast cancer to measure quality of life, and the Brief Symptom Inventory (BSI) 
was used to measure psychological distress. The disease continuum began at 
diagnosis followed by treatment phase, remission for less than one year, 
remission for greater than one year and finally, recurrent or terminal care.  
Spagnola et al (2003) found that quality of life declined from point of diagnosis 
into treatment then improved after treatment when patients were in short term 
and long term remissions.  Spagnola and colleagues’ findings illustrated that 
there was a significant benefit for earlier psychosocial screening of the patients.  
Another significant finding was that the majority of patients were willing to 
discuss quality of life issues, but would wait to be asked, and therefore the onus 
was on health care professionals to initiate these discussions (Spagnola et al 
2003). 
 
Kissane et al (2004) researched the psychosocial morbidity in women with 
breast cancer and compared early stage breast cancer patients with patients 
with advanced disease. Interviews and self reporting tools were used and the 
results found that 9.6% of patients with early stage breast cancer were 
experiencing major depression and 27.1% were experiencing minor depression. 
In patients with metastatic disease, 6.5% had major depression and 24.5% 
minor depression (Kissane et al 2004). Kissane and colleagues (2004) also 
found an association with cognitive attitudes and depression and that 
depression after diagnosis was higher with early stage breast cancer patients.  
Sægrov, Halding, (2004) also found that the period after diagnosis was stressful 
for breast cancer patients, although this qualitative study showed that the period 
between suspicion of cancer and diagnosis, was a greater period of stress.  The 
results from the twelve interviews also found that there was no follow up of 
patients regarding their need to talk to someone, nor was their any kind of 
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program to care for psychosocial needs (Sægrov et al 2004). The authors found 
that during the rehabilitation phase patients felt they were left to their own 
resources. The threat of new cancer cells was always with the patient and 
attending checkups was considered stressful (Sægrov et al 2004). This study 
highlighted the value of psychological and social support. 
 
Fukui et al (2003) also found the value of psychological support for breast 
cancer patients. Their aim was to examine the effects of a psychosocial group 
intervention on loneliness and social support in Japanese women with breast 
cancer. Fifty women aged less than 65 years old were involved in this study. It 
was conducted using a six week group intervention consisting of health 
education, coping skills training, stress management, and psychological support. 
The Loneliness Scale and a social support scale were used at baseline, six 
weeks and six months. The experimental group reported significantly lower 
scores than the control group, for loneliness, and significantly higher scores for 
number of confidants, satisfaction with confidants and satisfaction with mutual 
aid over the six month period (Fukui et al 2003). This study illustrated that the 
use of a psychological group intervention is beneficial, and that such a program 
was an effective way to address cancer patients’ psychosocial concerns.   
In contrast to the value of psychosocial support, Newell et al (1999) did a cross-
sectional study of the prevalence and predictors of physical symptoms, anxiety, 
depression and perceived needs. One hundred and ninety-five patients were 
assessed on their level of anxiety and depression using the Hospital and Anxiety 
Depression Scale (HADS) and by rating their perceived needs on a cancer 
needs questionnaire. Their results showed that 25% of participants had 
borderline or clinical levels of anxiety and depression and that the levels of 
anxiety and depression were interrelated with physical symptoms and perceived 
needs. Participants reporting four or more physical symptoms were much more 
likely to have elevated anxiety and depression compared to those with less than 
three physical symptoms. The results also showed that having lots of support at 
home was a predictor of patients having elevated levels of depression. The 
author felt that this may be due to the patients’ perception of dependency and 
lack of autonomy. 
 
A further study by Montazeri et al (2000) differed from the previous ones in the 
correlation with anxiety and depression. The study measured anxiety and 
depression in Iranian breast cancer patients before and after diagnosis using the 
(HADS). One hundred and sixty-eight patients participated in the study and 48% 
had severe symptoms of anxiety at both baseline and follow-up. Twenty percent 
of participants had borderline levels of depression pre treatment and this 
decreased by 6% at follow up. Eighteen percent of participants had symptoms of 
severe depression at first visit to the clinic and this decreased by 4% at follow up 
(Montazeri et al 2000). The researchers described these findings as 
'challenging' because most studies had found that breast cancer patients that 
had experienced severe levels of anxiety, also experienced high levels of 
depression. Their results also showed that progressive disease and a lower 
performance status were predictive factors of anxiety and depression. The 
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authors described how the low level of depression compared to anxiety levels, 
could be attributed to Iranian women having strong family ties, support, and 
religion that plays an important role in the patient’s life (Montazeri et al 2000). 
These factors were not measured in this study but the author proposed the 
relevance of these. Other factors that could have contributed to the results were 
timing of interview, disease status, demographic characteristics, and the 
instrument of use.    
  
Depression and adjuvant chemotherapy 
The relationships between depression and adjuvant chemotherapy have been 
well researched. The side effects experienced by patients receiving 
chemotherapy, have been closely related to psychological issues. Tish Knobf 
(1990) and Byar et al (2006) have reported a specific time when depression is at 
its highest with breast cancer patients. Beyond these studies there is little 
evidence to identify that there is a particular time period within a patient’s 
treatment cycle of adjuvant chemotherapy to develop depression.  
 
One study identified differences in fatigue, other physical symptoms, 
psychological symptoms and their relationship to quality of life during 
chemotherapy (Byar et al 2006). The study was a longitudinal descriptive survey 
of 25 patients using the Piper Fatigue Scale, Hospital and Anxiety Depression 
Scale (HADS), Symptom Experience Scale and Medical Outcomes Study Short 
Form General Health Survey, which was administered 30, 60 and 90 days after 
the last treatment and one year after their first treatment. The surveys were also 
administered during treatment, which was for two baseline days at the beginning 
of treatment, and then the first seven days after each of the patient’s four 
chemotherapy treatments. Fatigue was rated moderately intense during 
treatment and then decreased with time. Sleep disturbances and pain were the 
most frequent, intense and distressing physical symptoms. Anxiety was rated as 
highest at the beginning of the participant’s treatment and depression was 
highest during the fourth chemotherapy treatment. Fatigue correlated with other 
physical and psychological symptoms at times during and after treatment. 
Higher fatigue correlated with a lower quality of life. By using the HADS, the 
study found that depression was lower at baseline, peaked at treatment four 
then returned to normal after treatment ended. Anxiety was reported more 
frequently than depression. This study supports a link between depression and 
fatigue which were highest at the fourth treatment of chemotherapy.  The 
findings also illustrate the need for routine screening and ongoing assessments.  
The results regarding the point in which depression was highest is consistent 
with Badger et al’s (2001) findings which looked at depression burden within the 
more narrow parameters of a diagnosis of breast cancer. 
 
Tish Knobf (1990) has written a review of literature surrounding the needs of 
patients with breast cancer to illustrate that knowledge of predictable 
psychological responses through the various phases of treatment is a critical 
element of the rehabilitation phase. The importance of health care providers 
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anticipating problems so that they can prepare the patient and incorporate early 
interventions to minimize symptoms has been highlighted. The paper related 
breast cancer physical and psychological symptoms and discussed these 
relationships at diagnosis as well as during surgery, the rehabilitation phase 
from surgery, radiotherapy, and adjuvant chemotherapy. The author reported 
fatigue to be common with breast cancer therapies, and that ratings of distress 
and difficulty increased with the number of chemotherapy cycles. Mild to 
moderate levels of psychological distress were predictable during and after 
primary treatment, and this continued longer than a year after mastectomy (Tish 
Knobf 1990). 
 
One hundred and sixty-nine participants reported on their level of depression, 
the severity of side effects and the number of side effects in a study conducted 
by Badger et al (2001). Self help interventions were used repeatedly during the 
course of treatment in women with breast cancer. The self help interventions 
were shown to significantly reduce fatigue, pain and nausea in the participants. 
The researchers’ commentary included the need for identification and treatment 
of depressive symptoms early in adjuvant chemotherapy. As with pain and 
nausea, the researchers were of the opinion that there is a need to capture the 
frequency and intensity of a depressive experience (Badger et al 2001). 
Another study examined the quality of life of patients with a history of breast 
cancer who had received previous treatment with adjuvant chemotherapy 
(Broeckel et al 2000).  The sample was 61 women with a history of breast 
cancer but who were currently disease free, and who had received adjuvant 
chemotherapy 3-36 months prior.  The authors used a comparison group of 59 
women who had no history of breast cancer.  The results were consistent with 
Broeckel et al’s (2000) prediction that the post chemotherapy group scored 
lower on quality of life issues using the Centre for Epidemiologic Studies 
Depression Scale (CES – D) and the Medical Outcomes Study Short Form 36 
(SF – 36).  Younger, unmarried women scored higher in regard to poor mental 
well-being and greater depressive symptoms.  This is consistent with a literature 
search by Bottomley et al (1997) who reported that young women were at 
greater risk of developing depression. Time was also significant as the time 
passed since the participant received chemotherapy resulted in greater 
depressive symptoms.  None of the demographic or medical variables were 
significant.  Broeckel et al (2000) concluded that breast cancer patients 
experience problems in multiple quality of life domains following adjuvant 
chemotherapy and there is a need for interventions to improve the quality of life 
in these patients. 
 
Miranda et al (2002) used the Beck Depression Inventory (BDI) both before and 
after neoadjuvant chemotherapy, to verify if depression influenced treatment 
outcome for patients with advanced uterine cancer or breast cancer. Twenty-two 
patients with advanced uterine cancer and 20 breast cancer patients had three 
courses of neoadjuvant chemotherapy. There were no significant differences in 
the number of depressed patients before and after treatment and levels of 
depression were not significantly different for either type of cancer. After 
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treatment, the number of breast cancer patients that had depression increased, 
while the number of uterine cancer patients with depression decreased. Patients 
that responded to treatment were less depressed than those who showed 
increases in tumour activity (Miranda et al 2002). The author reported on tracing 
the course of patients’ depression and its manifestation yet the BDI was only 
administered at two separate intervals during the course of the patient’s 
treatment which may not fully represent the course of depression. 
 
Cowley et al (2000) investigated how women receiving adjuvant chemotherapy 
cope with their treatment.  The qualitative study looked at patients’ 
preconceptions about adjuvant chemotherapy, their information needs and the 
impact of treatment.  Cowley et al (2000) reported that a cancer diagnosis 
causes disruption to a patient’s self-identity, body image and time experience. 
Although the responses varied, the participants responded to these changes by 
seeking social support, developing coping mechanisms and striving to re-
establish normality. The paper discussed the rollercoaster effect that patients 
experience through the course of a chemotherapy cycle. In this research, the 
patients were having 6 cycles of chemotherapy every 3 weeks and Cowley et al 
(2000) illustrated the psychological ups and downs that patients experience 
while going through this cycle of chemotherapy. They reported that patients’ 
energy levels diminished over the course of the 6 cycles and this also had an 
accumulative mental and physical effect on the patients’ morale and motivation.   
 
Colleoni et al (2000) performed research on depression and the degree of 
acceptance of adjuvant cytotoxic drugs. This study investigated the interaction 
between psychological attitude and outcome in early stage breast cancer 
(Colleoni et al 2000) and related it to a tendency of depressed patients to be 
less proactive in obtaining health care.  The authors assessed the link between 
depression and degree of acceptance of adjuvant chemotherapy in a group of 
patients who required psychological support after surgery, compared with a 
control group of patients who underwent surgery for similar stage breast cancer 
and were offered similar treatment.  The study illustrated that depression 
represents a crucial factor for acceptance of adjuvant chemotherapy, and 
suggested that psychological support and treatment of depression might 
increase acceptance of chemotherapy and possibly improve prognosis of 
patients (Colleoni et al 2000). 
 
Carter et al (1997) performed a study to determine whether receiving six cycles 
of chemotherapy adversely affected the quality of life of patients with 
gynaecological cancers.  The sample was 60 patients diagnosed with a variety 
of gynaecological cancers with the consistent factor that all had received six 
cycles of chemotherapy each.  The FACT – G quality of life form was modified 
and used by participants.  Quality of life responses for patients with cervical 
cancers were not significantly different to patients with ovarian, uterine and 
vulvar tumours.  An improvement in physical well-being from cycles 2-5 was 
significant and emotional well-being and functional well-being improved from 
cycle 1-6 although results were not significant.  A decline in social well-being 
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and relationship with the doctor was noted.  The authors concluded that 
treatment with six cycles of chemotherapy for patients with gynaecological 
cancers resulted in an overall improvement in quality of life from the time of their 
first treatment, yet the changes were not statistically significant (Carter et al, 
1997). 
Depression and oncology nurses 
The physical and psychological aspects associated with a patient’s treatment 
are an integral part of providing holistic care. Just as oncology nurses are 
trained in the assessment of patients and provision of treatment for cancer such 
as chemotherapy or radiotherapy, it is an important issue for oncology nurses to 
be aware of the psychological implications that cancer and the treatment for 
cancer has on the patient. Nurses could be trained to assess for depression and 
refer patients if the patients are experiencing psychological difficulties (Maguire 
et al 1994). Strong et al (2003) and McDonald et al (1999) researched the 
concept of using specially trained nurses to help with the assessment and 
diagnosis of depression.  Strong et al (2003) concluded that a multidisciplinary 
psycho-oncology team approach is still needed to effectively treat patients. The 
study suggested that a specially trained nurse can deliver depression 
management in a cost effective manner with benefits to the patient. McDonald et 
al’s (1999) research found that there was a tendency, by the nurses, to 
underestimate the level of depressive symptoms in those patients that were 
more severely depressed.  Badger et al (2001) commented that it is critical that 
clinicians enquire about side effects of treatment, because patients may not 
initiate conversations about depression experiences because of societal 
attitudes and beliefs about depression. They also stated that there was a need 
to document well the effectiveness of any treatments provided (Badger et al, 
2001). 
In support of nurses assessing for psychological issues, Paraska (2003) has 
researched the presence of depression that may confound disturbances in 
cognitive dysfunction. This prospective study indicated that breast cancer nurses 
should report any manifestations of depression that persist for two weeks or 
more. They should be assessing their patients for a depressed mood; 
diminished interest or pleasure; weight loss; sleep changes; diminished ability to 
think or concentrate; feelings of worthlessness and suicidal ideation (Paraska et 
al 2003). 
In addition to the studies above, there has been further study into the nurses’ 
ability to assess their patients for depression. Zhao et al’s (2003) research 
explored the discrepancy between patients and nurses’ assessments of patients’ 
conditions when undergoing adjuvant chemotherapy.  The scores between 
nurses and patients were compared for variables on the European Organisation 
for Research and Treatment of Cancer – Quality of Life Questionnaire (EORTC-
QLQ – C30).  Zhao et al (2003) reported significant differences between nurses 
and patients scores on cognitive function, fatigue, constipation and financial 
impact. Moderate differences were recorded on physical functioning, nausea 
and vomiting, diarrhoea and financial impact. Overall, the authors reported a 
poor correlation between the patients’ and nurses’ scores. This study highlights 
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a need for education and specialist oncology nurses to avoid such discrepancies 
in nurses’ assessments. It is important to recognize patients who are at risk of 
factors that will affect their quality of life and to implement early interventions to 
manage these. Zhao et al (2003) have highlighted the importance of a thorough 
assessment of the patient to help overcome this. Padilla and Grant as cited in 
Zhao et al (2003) have stated that a patient’s quality of life was influenced by 
how well nurses were able to help patients adjust to their changes of physical 
functions or symptoms that were induced by the cancer or its treatment. Quality 
of life is an important element of holistic nursing practice.  
 
Depression Assessment Tools used in Cancer Research 
Depression may go undetected and thereby untreated in oncology practice. The 
importance of appropriate assessment and screening tools has been 
emphasized. There are many instruments currently in use for assessing 
depression in cancer patients. Widely used assessment instruments for 
screening are the Beck Depression Inventory, the Hospital Anxiety and 
Depression Scale, the Structured Clinical Interview according to the Statistical 
Manual of Mental Disorders (Wedding et al 2007). Researchers can select from 
a variety of instruments based on weighing the ease of use for the study 
population. Some assessments, like the Structured Clinical Interview for the 
Diagnostic and Statistical Manual of Mental Disorders (SCID), may be useful in 
research studies, but they are too time consuming for a clinical setting. Shorter, 
self-report assessments may be easier to implement and are good guidelines for 
further screening (Agency for Healthcare Research and Quality 2002). Wedding 
et al (2007) reports the Beck Depression Inventory as the most widely used 
instrument to screen for depression and to measure its intensity. 
A number of researchers have used depression assessment tools in cancer 
research.  Pascoe et al (2000) incorporated the use of the Hospital and Anxiety 
Depression Scale (HADS) when researching anxiety and depression. Their aim 
was to estimate the prevalence of anxiety and depression within a cross section 
of cancer patients in the Sydney region, and to assess the use of and degree of 
satisfaction with available support services. Five hundred and four participants 
were required to complete the HADS, and a questionnaire to determine the use 
of support services, as well as clinical and demographic information (Pascoe et 
al 2000). The prevalence of depression was 7.1%, and anxiety rated 11.5%. Of 
the patients that were experiencing clinically significant anxiety and depression, 
75% had not received any counselling or psychological treatment. Predictors of 
depression were restricted activity levels, advanced disease, non-English 
speaking background and being female (Pascoe et al 2000). Although the 
number of patients with significant anxiety and depression was low, the number 
of patients accessing treatment or counselling was also low. Pascoe et al (2000) 
agree with McDonald et al (1999) that screening of patients might enable 
immediate identification of a depressive illness and therefore enable referral for 
further testing and treatment. 
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Love et al (2004) wanted to compare the HADS with another self-reporting 
questionnaire, the Beck Depression Inventory (BDI). The aim of the study was to 
compare the two self reporting questionnaires for identifying possible depression 
in women with metastatic breast cancer (Love et al 2004). Structured psychiatric 
interviews were performed and the BDI-Short Form and the HADS were 
administered to 227 women with metastatic breast cancer. The accuracy for 
identifying DSM-IV-defined major depression and minor depression was 
examined. Almost thirty-three percent of patients were found to satisfy the 
criteria for a depressive disorder. Overall, the two scales performed similarly in 
identifying major depression, while the BDI-SF was more useful in screening for 
DSM-IV major or minor depression categories (Love et al 2004). 
 
A team from the University of Liverpool has created a method of testing for 
depression so clinicians can introduce additional treatment to enable patients to 
cope with cancer more effectively. The Brief Edinburgh Depression Scale 
(BEDS) was originally developed from sufferers of post natal depression. The 
BEDS has been trialled on 246 patients with advanced cancer. A quarter of 
those were shown to have depression that was not previously diagnosed. The 
tool was developed due to the difficulty of determining the difference between 
the symptoms patients were experiencing were due to disease or depression 
(University of Liverpool 2007). A member of the research team that created this 
new screening tool stated that “it is vital that depression during cancer is 
identified so clinicians can implement appropriate treatment and intervention in 
the form of drugs or therapy, so the patient receives the optimum care possible” 
(University of Liverpool 2007 p1). 
 
Conclusion 
The literature demonstrates depression remains an important factor related to 
cancer. Studies within this literature review demonstrated that psychological 
support for people with cancer was vital to the patient's recovery.  A number of 
researchers have also recognized the need for earlier and more advanced and 
accurate screening of psychological issues for patients with cancer.  
Studies in this literature review supported the need for oncology nurses, who are 
already specially trained in the delivery of cancer treatment, to also be trained 
and capable of assessing and screening for psychological problems in their 
patients. The benefit and necessity of having specialist oncology nurses able to 
assess a patient’s psychological needs was highlighted. A means to assist the 
nurses in this development would be to increase the nurses’ awareness of 
patient’s susceptibility to developing depression. It would be beneficial to nurses 
to be aware of patients’ susceptibility to depression and a potential time frame 
during the adjuvant chemotherapy cycle where patients are more likely to 
develop depression. Researchers have not been able to quantify when 
depression occurs and its intensity across a variety of cancers and 
chemotherapies.  Side effects of chemotherapy, both physical and 
psychological, had an accumulative effect and symptoms became worse as the 
treatment progressed. For women with breast cancer receiving adjuvant 
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chemotherapy, the fourth treatment cycle was when depression was at its 
highest. The literature on depression in cancer therapy, and particularly the 
timing of depression is scant.  Further investigation needs to occur across a 
broader range of cancers and treatment to identify the onset of depression. 
Such research would ensure that health care professionals are aware of the 
importance of screening, assessment and early intervention of psychological 
issues.  
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CHAPTER  3: METHODOLOGY 
Ethical Considerations 
This study followed appropriate processes for ethical considerations. The 
research ethics committees of the University of Southern Queensland and the 
Toowoomba Health Service District approved the study (Appendix A). All 
participants gave written informed consent.  Human rights were protected by 
respecting self-determination by informing the participants about the research, 
voluntary participation and the right to withdraw. The researcher was 
responsible for ensuring that the research project had a low probability for 
causing harm. The researcher was prepared to deal with any risks, 
inconveniences and discomforts that might have arisen. If a participant’s 
response to the survey indicated a level of depression, the researcher advised 
the participant to seek appropriate attention by a trained professional and 
withdrew the participant from the study.  The oncology clinic Nurse Unit 
Manager in charge of the unit where the participant was receiving treatment was 
also notified to ensure follow-up. The participants were informed (Appendix B) 
that participation was entirely voluntary and that they were able to withdraw from 
the study at any time themselves with no consequences. 
The rights of privacy and confidentiality were preserved.  Only the principal 
researcher knew the identity of the participants. Complete anonymity was not 
possible due to the need for correspondence with the participants. The list of 
participants was stored away from participants’ responses. The data was treated 
confidentially.  All data was stored as a hard copy in a locked filing cabinet. It 
was also stored electronically under password protected data files on a 
password protected computer. The data is not identifiable to anyone as a coding 
system has been used and only the Principal Researcher has access to it.  
 
Research Question 
The research questions were:  
1) Is there a particular point within the chemotherapy treatment cycle when                 
patients are vulnerable to developing depression;  
2) Is there a relationship between the number of side effects experienced by     
patients receiving adjuvant chemotherapy and depression; 
      3) What is the relationship between depressive symptoms, patient                      
characteristics and side effects? 
 
Research Design 
The research design for this study included a prospective, longitudinal, 
descriptive method. The objective of a longitudinal design is to see whether a 
phenomenon changes over time (Roberts & Taylor 2002). In this study, the 
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phenomenon was the patient’s mood. The simple descriptive method allows the 
researcher to use an inexpensive and relatively short survey to assist in best 
answering the research question.  The variables are known and there are no 
comparison groups.  In choosing this design the researcher considered the 
question that they were asking, the group of people that they wanted to ask and 
the identifying aspects of the group. The question being asked regarding 
depression can be a sensitive topic for some people and the question was being 
asked of a vulnerable group of people going through a stressful period in their 
lives. Therefore, it was important to select the method of least inconvenience to 
the participant but which could still best answer the question. The survey was 
chosen as it was an existing tool for measuring depression that has been tested 
for reliability and validity and would be also, less imposing to the participant than 
a questionnaire or interview. 
  
Data was collected using a survey method and entered into the statistical 
program SPSS 15 for Windows. 
 
Data was analysed using descriptive analysis to answer question one, and 
inferential and correlation analysis to answer questions two and three. There 
was also unexpected qualitative material that was provided by the participants 
which has been included in this thesis. It has not been analysed as it does not 
directly answer the research questions, but gives valuable qualitative insight into 
what the patients were experiencing (See Appendix E).  
 
Study Region and Setting 
The Nurse Unit Managers of two oncology clinics in the city of Toowoomba, 
Queensland, Australia were asked to participate in the study. Toowoomba is the 
Garden City of Queensland with the population of over 90,000 and is a 90 
minute drive from Brisbane, Queensland’s capital city. It is serviced by 3 major 
hospitals, (2 private) and has a comprehensive range of health services 
including a stand alone day surgery unit and a radiotherapy unit. In Toowoomba 
there are over 200 medical practitioners covering various specialties.  There are 
also a number of educational facilities such as 12 pre-schools, 11 private 
primary school, 16 state primary schools, 5 secondary state schools, 10 private 
secondary schools, 7 boarding schools and 3 tertiary institutions. The city is 
renowned for its natural environment, world class gardens, attractive parks and 
tree lined streets. The city has a number of attractions and offers residents a 
wide variety of lifestyle opportunities (Toowoomba.org 2008).  
 
 For logistical reasons, two out of three oncology clinics within the city were 
included in the study, one state run and the other private. The logistical reasons 
included: a) financial reasons in that this study is for an unfunded two year 
master thesis and b) to have a regional focus due to the issue surfacing whilst 
the researcher was working in a regional oncology clinic. 
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The oncology clinics that were chosen to be included in the study were 
St.Andrew’s Hospital Cancer Care Unit and the chemotherapy unit of the 
Toowoomba Health Service. St.Andrew’s Hospital is a 137 bed, acute care 
private hospital. It services Toowoomba and its surrounding towns i.e. 
Tenterfield, Goondiwindi, St.George, Roma, Kingaroy, Gatton and the Lockyer 
Valley. The John Steadman Unit is the Chemotherapy unit at St.Andrew’s. 
Chemotherapy is given by trained Registered Nurses under the direction of the 
patient’s General Practitioner or Specialist Consultant. A clinical haematologist 
and oncologist visit the unit on a weekly basis (St.Andrews Hospital 2008).  
 
The Toowoomba Health Service services the state electorates of Callide, 
Lockyer, Toowoomba North and Toowoomba South, Nanango, Cunningham, 
Darling Downs, Southern Downs and Warrego. The chemotherapy unit recorded 
1,264 episodes of care for the 2005/2006 period. The unit is staffed with 
registered nurses, social worker, psychologist, pharmacist, registrars, palliative 
care consultant and clinical oncologists (Queensland Government 2008). 
 
The data collection was completed over a twelve month period. The total 
number of patients that received adjuvant chemotherapy between the two 
oncology units was 78 patients.  
 
Research participants and sample 
The target population was patients that had been diagnosed with cancer that 
required adjuvant chemotherapy. The sample was drawn from patients 
diagnosed with cancer requiring adjuvant chemotherapy at the chosen oncology 
units.  
Inclusion Criteria:  Participants included were  
a.  between the ages of 18 – 80 years old (due to the fact that chemotherapy is 
not usually offered or advantageous to patients over the age of 80, and younger 
patients requiring chemotherapy are generally transferred to Brisbane for their 
treatment) 
b. able to speak and write the English language or have access to an 
interpreter 
c. Mentally competent.  
 
Exclusion Criteria:  If a patient failed to return a survey after two reminder letters 
then they were excluded from the study.   
 
Participants that were scored as depressed using the Beck Depression 
Inventory – II were withdrawn from the study at the time that the survey with a 
positive result for depression was received. The total number of participants 
withdrawn from the study was ten. The time points at which they were withdrawn 
varied. Two participants were withdrawn after fortnight three into their 
chemotherapy cycle. Two were also withdrawn after fortnight four. Three 
participants were withdrawn from the study after fortnight five and then three 
again after fortnight seven.  
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Research procedures  
To conduct this study, the participants were required to complete three different 
forms. Firstly, at the beginning of their treatment (this was either on the first day 
of their treatment or at a pre treatment meeting which are generally held a few 
days prior to the first treatment) they were asked to complete a few short 
questions to obtain demographic information. This provided essential 
information such as which cancer they had, what type of chemotherapy they 
were receiving and if they had suffered from depression in the past. Secondly 
they received a questionnaire called the Beck Depression Inventory – II (BDI-II) 
to identify if they were suffering from depression.  They were asked to complete 
it at fortnightly intervals, from the beginning to the end of their treatment. The 
number of surveys that they received was dependant on the type of 
chemotherapy that they were having. Different chemotherapy treatments are 
given over different periods of time dependant on the type of cancer being 
treated and the types of chemotherapy being used in the treatment.  
 
Thirdly they received a short form to identify any side effects that they may have 
been experiencing. The researcher had designed their own questionnaire on 
side effects as they only wanted information specific to side effects of 
chemotherapy. The symptoms listed in this form are that which are commonly 
found to be symptoms of chemotherapy (Otto, 2001). This form was to be 
completed with the fortnightly BDI-II.  The data gained from the side effects form 
was to highlight any side effects that were particularly frequent and common to 
patients that also suffered from depression.  
 
The Nurse Managers of the oncology clinics were notified if patients scored a 
mild to severe rating on the Beck Depression Inventory-II. They were able to use 
this information to initiate supportive psychological care for the patients. The 
patient was then informed that they no longer were required to complete the 
surveys as their result had answered the question of a specific time within the 
treatment cycle when patients were more vulnerable to developing depression. 
 
Recruitment of Participants 
Contact with the sample group at St.Andrew’s Hospital was initiated by the 
Clinical Nurse in charge of the oncology unit. The researcher provided flyers and 
education to the clinical nurse and staff on the issues of the study and the use 
and importance of the paperwork. The flyers were included in the education 
packages that oncology nursing staff gave to their patients prior to them 
commencing their treatment.  The clinical nurse discussed participation in the 
study with the patient and allowed the patient to take the forms home and 
forward them to the researcher by mail in self addressed envelopes.   
 
The data collection process was extended due to low numbers of participants.  
After discussion with associates, the decision was made to extend the site of the 
study to a larger institution with greater numbers of patients and therefore 
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greater exposure to the study. The data collection process was again extended 
due to the slow process of ethical clearance.  To enhance the participation rate 
at the new site, the researcher gained permission from the Nurse Unit Manager, 
to initiate the study personally. This was more convenient for the oncology unit 
due to the work demands of the oncology nurses and the extra time needed if 
they were to perform this extra duty. Education was provided to the oncology 
nurses and the documents and relevance of the study explained.  
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CHAPTER 4:   DATA COLLECTION  
Collection Tools 
A longitudinal survey method was chosen to reflect significant changes 
throughout the course of a patient’s treatment, and to best answer the research 
question.   The instrument of use was the Beck Depression Inventory (BDI-II) 
(See Appendix C), which was originally introduced by Beck, Ward, Mendelson, 
Mock, Erbaugh, in 1961 as the BDI. It was revised in 1996 to become the BDI-II, 
and in doing so, became more congruent with the diagnostic criteria for 
depression listed in the DSM-IV (Groth-Marnat 2003). The content of the survey 
included factors that reflect negative attitudes towards self, performance 
impairment and somatic disturbances as well as general factors of depression.  
The survey evaluates 21 symptoms of depression, 15 of which cover emotions, 
4 cover behavioural changes and 6 cover somatic changes. Each symptom is 
rated on a four point intensity scale and scores are added to give a total ranging 
from 0 – 63. The higher the score, the more severe the depression (Beck, Steer, 
Garbin 1998).  The BDI-II was given to the participants to complete on a 
fortnightly basis from the beginning of their treatment, usually at the time of their 
first treatment, until they finished their treatment.  
 
Evaluation of the BDI-II has found that internal consistency ranges from 0.73 – 
0.92. At first test-retest reliability was not recommended by Beck as he 
suggested that scores could be inflated due to memory factors. After further 
reviewing of test-retest reliability, Beck found that regardless of whether the 2 
tests were administered at 2 or 6 week intervals, the scores in the BDI did reflect 
changes in the clinical depth of depression. Test-retest reliability ranges from 
0.48-0.86 depending on the interval between re-testing and the type of 
population.  Evaluation of content, concurrent and discriminant validity, as well 
as factor analysis were also favourable.  Content of the BDI-II items were 
derived from clinicians regarding symptoms of depressed patients.   Moderate 
correlations have been seen with Hamilton Psychiatric Rating Scale for 
Depression (.71), Beck Hopelessness Scale (.68) and the Depression Anxiety 
Stress Scale (.88) (Groth-Marnat 2003).  The BDI-II has also been used to 
discriminate between anxiety and depression, loneliness and stress.    
 
Demographic information was collected in the initial stages. The information 
required included gender, date of birth, type of cancer, type of chemotherapy, 
whether the patient had been diagnosed with depression before, and if so, what 
type of treatment did they receive, and how long ago were they diagnosed. This 
information was to ascertain the important variables that may or may not affect a 
patient and whether they experience depression with this treatment. The data 
collected from the demographic information are also used to answer questions 
two and three of the research questions: 
2) Is there a relationship between the number of side effects experienced by 
patients receiving adjuvant chemotherapy and depression; and,  
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3) Is there a relationship between these characteristics, the side effects of 
chemotherapy and depression. 
 
The final information obtained from the patients was a questionnaire on any side 
effects that they had experienced in the previous two weeks. This information 
was also used to evaluate questions two and three of the research questions.  
This was investigating the possibility of a relationship between the patients who 
demonstrated depression and concomitant side effects of the chemotherapy or 
particular characteristics these patients may have. 
 
Collection Procedures 
Initial contact with patients at St.Andrews Hospital was made by the Nurse Unit 
Manager.  After receiving the first completed survey in the mail, the researcher 
then mailed the participant another BDI-II and a side effects form each fortnight. 
The participants were asked to complete it at fortnightly intervals, from the 
beginning to the end of their treatment.    
 
The data collection process was extended due to low numbers of participants, 
especially in the early months of the study.  After initiating the study at the 
Toowoomba Health Service and agreeing on reasonable contact between the 
researcher and patients, the Nurse Unit Manager notified the researcher of new 
patients and when they would be starting their treatment via electronic mail or 
phone. The nursing staff at the oncology unit then provided an introduction of 
the researcher to the patient. After initial contact with the participants, the 
researcher then continued contact via mail with the participants as with the other 
sample group. The participants had the subsequent appropriate forms mailed to 
them at regular fortnightly intervals. To help encourage participation and 
compliance, the researcher included a note, thanking the participant for their 
support in the study and to remind them of the date that the survey was due to 
be completed. A self addressed stamped envelope was also included as a 
matter of convenience for the participant. Overall the number of participants that 
responded from St. Andrews Hospital was 57% with the remaining 43% 
respondents from the Toowoomba Health Service. 
 
The researcher maintained a diary of all outgoing and incoming mail and its 
contents. This provided a tracking tool for the researcher of what had been 
distributed and received, and therefore was able to easily identify if any 
responses were still outstanding. If a response had not been received from a 
participant within two weeks, a reminder was mailed or emailed to the 
participant. If no response was then received within a week, another reminder 
was mailed or emailed. If there was still no response, the participant was 
excluded from the study.  There were no participants excluded from the study on 
the grounds of failing to respond, as they all responded after a reminder letter 
until they completed their treatment or if they recorded a level of depression and 
they were excluded for this fact. 
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Storage of Data 
As survey responses arrived in the mail, the data for each patient were 
categorised into the fortnightly period in which the survey was completed to 
correlate where they were in their treatment cycle.  Each patient was given a 
code so that subsequent questionnaires could be compared.  Data was then 
entered into the SPSS database which included the patient’s code, gender, age, 
type of chemotherapy, type of cancer, their score from the survey and any side 
effects they reported.  The data was also stored in hard copy in a locked filing 
cabinet. 
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CHAPTER 5: STATISTICAL  ANALYSIS 
Prior to the implementation of the data collection tools, it was decided to enter all 
data into the SPSS program. The student version 14.0 was initially used but the 
program was not big enough to enter all the variables required to load the data 
over the period of 9 fortnights for some patients. The SPSS program was 
upgraded to SPSS 15.0 for Windows as it would support the data. 
 
All data was entered manually into the SPSS program and once all data had 
been entered, it was analysed.  The plan for the data analysis to best answer 
the research questions came from the question and design of the study. 
Therefore the data was analysed in three separate sections in relation to the 
research questions. Initially, all data was entered into one output of SPSS. To 
make the analysis easier, the data was then segregated into depressed patient’s 
data, and the third data set was BDI-II scores. 
 
For question 1, descriptive and inferential methods were used to analyse the 
data. Firstly, descriptive analysis began by reporting on patient characteristics 
such as age, gender, type of cancer, type of chemotherapy and history of 
depression of the sample group.  The participant’s age was represented on an 
interval scale. The remaining characteristics were analysed using frequency 
distributions.  Mean scores were calculated for age and depression scores. 
 
Quantitative data analysis of the BDI-II questionnaire began by first totalling the 
patient’s scores on the survey.  Each question in the survey was added as a 
variable into the SPSS program and each response to the questions was 
entered thus illustrating how each participant answered to get the score that 
they did. This allowed the depressed participants to be easily identified and a 
new data set was created to view the data of the depressed participants on their 
own, and assist the analysis.  
 
Missing Data 
Missing data was managed in the data set of depressed participants. This was 
done using the SPSS 15.0 program. The SPSS 15.0 program has a missing 
value analysis procedure which may help find any patterns to the missing data. 
The missing data was completely random in this study and for participants that 
were excluded due to scoring a level of depression, the missing data was 
analysed using the exclude pair wise option which excludes the person only if 
they are missing the data required for the specific analysis. They are still 
included in the analysis for which they did have data.  The time point in which 
there was missing data and this analysis method was used was at fortnight 
three, four, five and seven.  
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Assumption Testing 
Assumption testing was performed prior to evaluation and testing the 
significance of the data. To meet the criteria of assumption testing, the scale of 
measurement used was interval. The sample of the population was non-
probability purposive. The tests of normality are illustrated using histograms or 
normal probability plots and significance is tested using Kolmogorov-Smirnov 
and Lilliefors significance level and Shapiro- Wilk statistics as the population 
was less than 100. If the significance level was greater than 0.05 then normality 
was assumed. When skewness and kurtosis were extreme, transformation was 
used. The method of transformation was computing as it was available with the 
SPSS program and it was able to provide a composite score.  
 
The levels of significance of the participant’s scores on the BDI-II were then 
analysed. Paired T-tests were performed to illustrate the significance of the 
scores. 
 
The depressed participant’s data set was also used to answer the remaining 
questions of the research problem. In relation to the second and third research 
questions, inferential statistics of correlation analyses were appropriate. Multiple 
regression analysis was not possible due to the low sample number. 
 
To answer question 2, it was necessary to look at the numerical relationship 
between participant’s depression scores and the number of side effects they 
experienced. The frequencies of side effects were initially identified and the 
highest rated side effects, i.e. side effects that were reported by five or more 
depressed participants, were then used in the correlation analysis with 
depression scores. Correlation analysis is used to describe the strength and 
direction of the linear relationship between two variables (Pallant 2005). To 
inspect the correlation between the depressed participant’s scores and the 
number of side effects they experienced, cross tabulations were utilized. The 
Pearson R correlation coefficient and Spearman Rank were applied to 
determine the value of the correlation.  Pearson correlation is designed for 
continuous variables and can be used if there is one continuous variable (scores 
of a measure of depression) and one dichotomous variable (male/female).  
Pearson correlations take on a value of -1 to +1. The sign at the front indicates 
whether there is a positive correlation or a negative one. The size of the value 
indicates the strength of the relationship. On the other hand, a correlation of 
zero indicates no relationship between the variables (Pallant 2005). The 
Spearman’s Rank correlation is also used to determine the strength of a 
relationship between two continuous variables and has been used as an 
alternative to the Pearson correlation. The output from the Spearman Rank 
correlation can be interpreted in the same way as the Pearson correlation 
(Pallant 2005).  
 
The same procedure was used to illustrate the relationship between the 
symptoms of depression they reported, patient characteristics and the number of 
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side effects that they experienced. Again, the Pearson and Spearman Rank 
correlations were used to best describe any relationship and the strength of the 
relationship between the variables. 
 
Frequency distribution tables were used to highlight the frequency with which 
questions from the BDI-II were most commonly rated higher. The questions in 
the BDI-II that were scored at one or more and were recorded by six or more 
participants were used in the correlation analysis. Cross tabulations illustrated 
any correlations between questions from the BDI-II and patient characteristics 
and then questions from the BDI-II and side effects. Again the significance was 
illustrated using the Pearson R and Spearman Rank coefficients. 
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CHAPTER  6:  RESULTS 
Limitations 
 
The limitations of this study are significant and important to understand to fully 
appreciate the results. Limitations of the study included a small sample size and 
potential biases due to self-selection of the candidates and their self-evaluation 
of their experiences.   
 
The sample size of the study limits the ability to produce statistically significant 
results. The small sample size is a reflection of the population as the study was 
conducted at a regional centre. The study may have produced larger numbers if 
it were conducted at a metropolitan centre that services a larger population. In 
an attempt to overcome the small numbers the researcher used an additional 
oncology clinic half way through the data collection period. 
 
Self-selection bias is possible whenever the group of people being studied has 
any form of control over whether to participate. A participant’s decision to 
participate may be correlated with traits that affect the study, making the 
participants a non-representative sample. For example, people who have strong 
opinions or substantial knowledge may be more willing to spend time answering 
a survey than those who do not. In the general case, selection biases cannot be 
overcome with statistical analysis of existing data alone and an informal 
assessment of the degree of selection bias can be made by examining 
correlations between exogenous background variables and a treatment indicator 
(Roberts et al, 2002). The researcher has addressed this issue by examining the 
side effects participants were also experiencing at the time of reporting on the 
survey.   
 
Self reporting bias must also be considered as a limitation in this study. Self 
reports are affected by the accessibility and organisation of self relevant 
knowledge in memory, a number of expectations and cues associated with 
specific contexts, situations and cultures and by a variety of individual and 
developmental differences (Brinthaupt & Lipka, 1997). A method to overcome 
the self reporting bias is to include behavioural observation as an additional tool 
for measurement. This method of measurement was not available to the 
researcher due to the nature for which the study was conducted, the budget 
restraints of the study and the logistics of having a behavioural observationist 
available whenever a participant wished to complete the survey. The researcher 
did attempt to reduce the self reporting bias though by using a developed survey 
which has had reliability and validity tested and which results can be reviewed in 
Chapter 4.   
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Descriptive Statistics of the total sample 
The total sample size for this research was 26 participants.  From the sample 
group, the descriptive analysis reveals that the average age of participants 
receiving adjuvant chemotherapy was 54.8 years and the range of ages was 
from 35 to 77 years of age (Table 6.1). 
 
Overall, the descriptive data has shown that of the sample group, 80.8% were 
female (Table 6.2) and 64.5% were receiving treatment for breast cancer 
(Figure 6.1).  The more common chemotherapy combinations were those used 
for women with breast cancer, such as, FEC (fluorouracil, epirubicin and 
cyclophosphamide) 23.1% and Adriamycin, taxotere and cyclophosphamide 
19.2% (Figure 6.2). 
 
 
 
 
Age of Total Sample Group 
 
Mean 54.8077 
Range 42.00 
Minimum 35.00 
Maximum 77.00 
 
 
                                    Table 6.1 
 
 
 
 
 
 
 
Gender of Total Sample Group 
 
 Frequency Percent 
Valid Male 5 19.2 
 female 21 80.8 
 Total 26 100.0 
                           Table 6.2 
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Type of Cancer of Total Sample Group 
 
Bowel
Type of cancer 
Figure 6.1 
 
 
                   Type of Chemotherapy for Total Sample Group 
oxaliplatin and 
capecitabine
R-CVP
5FU & oxaliplatin
carbo, taxol
adriamycin, taxotere 
and cyclo
5FU and gemcitabine
FEC
5FU
Type of chemotherapy
 
Fig 6.2 
 
 
The descriptive data also identified that 19.2% of the participants had a 
previous diagnosis of depression (Table 6.3) and of those, 60% had received 
treatment with antidepressants (Table 6.4). One of the 19.2% of participants 
who had been diagnosed with depression had been diagnosed less than a 
month before starting treatment (Table 6.5).  This result could imply that this 
B-cell lymphoma 
Pancreatic 
Ovarian 
Breast
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participant developed depression around the time of their diagnosis of cancer 
although a more specific question would need to be asked to confirm this. 
 
 
 
 
Previous diagnosis for depression 
 
 Frequency Percent
Valid 
Percent 
Valid yes 5 19.2 19.2 
 no 21 80.8 80.8 
 Total 26 100.0 100.0 
     
                      Table 6.3 
 
 
 
 
 
Previous Treatment for Depression 
 
 Frequency Percent
Valid 
Percent 
Valid  21 80.8 80.8 
 anti-
depressant 
and 
counselling
1 3.8 3.8 
 anti-
depressant 
medication
3 11.5 11.5 
 counselling 1 3.8 3.8 
 Total 26 100.0 100.0 
            Table 6.4 
 
 
 
 
 
 
Time Diagnosed with Depression 
 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid less than 1 month 1 3.8 20.0 20.0 
 greater than 1 year 4 15.4 80.0 100.0 
 Total 5 19.2 100.0  
Missing System 21 80.8   
Total 26 100.0   
 Table 6.5 
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Depression Results 
There were 10 participants out of the sample of 26 that recorded some level of 
depression on the BDI-II. The frequency analysis revealed that fortnight 5 and 7 
of the participants’ treatment cycle (Table 6.6) was the period of time when 
patients were more likely to develop depression. To assist in confirmation of 
this data, the BDI-II scores for the depressed participants only were separated 
from the other data and the mean scores for each fortnight were calculated 
(Table 6.7). The results reveal a slight difference, but the main fortnight 
concerned (fortnight 5) remains the same. The mean score for fortnight 5 was 
9.11 and the frequency of participants recording depression in that time was 
30% (Table 6.7). 
  
                                                  
Episode of Depression 
 
 N 
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid       
 fortnight 1 26 2 11.8 20.0 20.0 
 fortnight 2 26 0 0.00 0.00 20.0 
 fortnight 3 26 2 11.8 20.0 40.0 
 fortnight 4 24 0 0.00 0.00 40.0 
 fortnight 5 22 3 17.6 30.0 70.0 
 fortnight 6 19 0 0.00 0.00 70.0 
 fortnight 7 19 3 17.6 30.0 100.0 
 fortnight 8 16 0 0.00 0.00 100.00 
 fortnight 9 16 0 0.00 0.00 100.00 
 Total  10 58.8 100.0  
       
Total   100.0   
              Table 6.6 
 
 
              
 
 
 
Mean Beck Depression Inventory Scores 
 
fortnight FN 1 FN 2 FN 3 FN 4 FN 5 FN 6 FN 7 FN 8 FN 9 
N 26 26 26 24 22 19 19 16 16 
          
Mean 6.23 6.15 7.15 8.58 9.11 7.19 8.11 5.0 5.96 
Standard 
deviation 1.45 2.14 3.68 5.24 4.58 1.6 2.48 0 1.31 
          
Range 7.00 8.00 16.00 27.00 18.00 7.00 10.00 .00 9.00 
              Table 6.7 
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Descriptive Statistics for Depressed Participants 
 
The frequency tables proceeding illustrate the results from the descriptive 
analysis of the demographic information for the participants that recorded a 
level of depression only.  The number of depressed participants was 10 (Table 
6.8). There were a greater number of female participants that recorded a level 
of depression than male.  This result is consistent with the previous research in 
this area.  
  
 
 
Gender of Depressed Participants 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Male 1 5.9 10.0 10.0 
  female 9 52.9 90.0 100.0 
  Total 10 58.8 100.0   
     
Total 10 100.0    
 Table 6.8 
  
  
 
 As a result of there being more females then males that were depressed, it 
was a likely result to see that more of the depressed patients were receiving 
treatment for breast cancer (Table 6.9) 
 
 
 
Type of cancer for Depressed Participants 
 
  Frequency Percent Valid Percent
Cumulative 
Percent 
Valid breast 8 47.1 80.0 80.0 
  ovarian 1 5.9 10.0 90.0 
  B-cell 
lymphoma 1 5.9 10.0 100.0 
  Total 10 58.8 100.0   
     
Total 10 100.0    
 Table 6.9 
 
 
 Another of the significant demographic results was the frequency of                       
whether the participants had a previous diagnosis of depression. Thirty percent 
of participants stated they had received a previous diagnosis of depression 
(Table 6.10).  The descriptive analysis demonstrated that depression during 
treatment was not necessarily predetermined by a previous history of 
depression. In patients with a history of depression, 3 out of 5 went on to 
experience depression during treatment. 
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                     Previous Diagnosis for Depression in Depressed Participants 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid yes 3 17.6 30.0 30.0 
  no 7 41.2 70.0 100.0 
  Total 10 58.8 100.0   
     
Total 10 100.0    
 Table 6.10 
  
 
From the sample group that did confirm a depression score, the results were 
analysed to see the frequency and validity of location.  Thirty percent of the 
sample group were from the Toowoomba local area.  Twenty percent were from 
Oakey with the remaining regions equally represented (Table 6.11). 
                      
Postcode 
                
  Frequency Percent 
Valid 4344 1 10.0 
  4350 3 30.0 
  4355 1 10.0 
  4380 1 10.0 
  4401 2 20.0 
  4370 1 10.0 
 2372 1 10.0 
  Total 10  
   
Total 100.0 
Table 6.11 
 
 
Assumption Testing 
Assumption testing was performed before the level of significance could be 
analysed. The scale of measurement used for the BDI-II scores was interval. 
The sample of the population was non-probability purposive. The tests of 
normality are illustrated using Histograms and Normal Q-Q Plots and 
significance was tested using Kolmogorov-Smirnov and Lilliefors significance 
level and Shapiro- Wilk statistics as the population was less than 100. If the 
significance level was greater than 0.05 then normality was assumed. When 
skewness and kurtosis were extreme, transformation was used. Power 
transform is from a family of functions that are appllied to create a rank-
preserving transformation of data using power functions. This is a useful data 
(pre)processing technique used to stabilize variance, make the data more 
normal distribution-like, improve the correlation between variables and for other 
data stabilization procedures (Pallant 2005). Power transformations were used 
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to improve interpretability and make them easier to visualise. The 
transformation of data in this analysis was not extensive and should not alter 
the interpretation of data greatly.  Transformation was applied in two instances 
and of which one did not make any improvements. Transformation was applied 
to the mean score of fortnight four and fortnight nine. The kurtosis for fortnight 
four was 11.010 and fortnight nine 11.9.   
 
Examples of the distributions have been illustrated in Figures 6.3 and 6.4 for 
fortnights two and three.   
 
Transformations were applied to fortnights four and nine. Fortnight four had a 
skewness of 2.876 and kurtosis 11.010 and significance was 0.00. Fortnight 
nine had skewness 1.2 and kurtosis 11.9 and significance 0.00 therefore 
normality could not be assumed.  After the transformations, the distribution for 
fortnight four appeared normal and the significance statistics support this. The 
distribution and significance for fortnight nine did not improve. The normal 
distributions for fortnight four are seen in Figure 6.5 and level of significance in 
Figure 6.6. 
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Figure 6.3 
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 Normal Q-Q Plot of Fortnight Three 
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Figure 6.4 
Transformed BDI Scores for Fortnight Four 
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Figure 6.5 
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Significance of Normality Distribution for Fortnight Four 
 
Kolmogorov-Smirnov(a) Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
.178 26 .033 .902 26 .018 
a Lilliefors Significance Correction 
 
Table 6.12 
 
 
 
 
Question Two and Three – Correlation Analysis 
To view the correlation between depression and the number of side effects that 
patients experienced, a correlation analysis was performed by viewing a cross 
tabulation of the two variables and assessing its significance using the Pearson 
R correlation coefficient and the Spearman rank correlation coefficient.  Results 
revealed that a greater number of side effects experienced on the day that the 
participants recorded a level of depression did not act as a predictor of a level 
of depression. The significance of these results as determined by the Pearson 
R and Spearman Rank coefficients reflects this (Table 6.14). 
 
The participant that experienced the greatest number of side effects rated only 
a mild level of depression.  The patient that rated a high level of depression i.e. 
severe only recorded having experienced one side effect. (Table 6.13) 
 
  
 Correlation of depression Score and Number of Side Effects of depressed participants 
 
  
  Number of side effects Total 
Depression score  1 3 4 5 6 7  
 14-19 Mild 0 1 2 1 1 1 6
  20-28 
Moderate 0 0 0 0 2 0 2
  29-63 
Severe 1 0 1 0 0 0 2
Total 1 1 3 1 3 1 10
   Table 6.13  
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Significance of correlation between depression scores and number of side effects of 
depressed participants 
 
  Value 
Asymp. 
Std. 
Error(a) 
Approx. 
T(b) 
Approx. 
Sig. 
Interval by 
Interval 
Pearson's R -.415 .268 -1.292 .233(c)
Ordinal by 
Ordinal 
Spearman Correlation -.226 .334 -.655 .531(c)
N of Valid Cases 10     
a  Not assuming the null hypothesis. 
b  Using the asymptotic standard error assuming the null hypothesis. 
c  Based on normal approximation. 
 
   Table 6.14  
 
 
 
When the entire sample group was analysed for the same correlation between 
BDI-II score and number of side effects, the same pattern was revealed (Table 
6.15). The total figure in Table 6.15 represents the total number of responses 
for those participants that rated in each category. The participants recorded the 
number of side effects they were experiencing on a fortnightly basis along with 
the BDI-II therefore the numbers are higher. The number of side effects 
experienced by the patients did not predict a score for depression. This is again 
reinforced by the Pearson R and Spearman Rank correlation analysis as shown 
below (Fig 6.16). 
 
 
 
 
Depression score and number of side effects for entire sample 
 
Depression 
score Number of side effects Total 
  0 1 2 3 4 5 6 7 0 
 0-13 normal 
4 4 17 17 19 13 17 7 98
  14-19 Mild 
0 0 1 1 2 1 1 1 7
  20-28 
Moderate 0 0 0 0 0 0 2 0 2
  29-63 
Severe 0 1 0 0 1 0 0 0 2
Total 4 5 18 18 22 14 20 8 109
   Table 6.15 
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Significance of correlation of depression score and number of side effects of entire 
sample 
 
  Value 
Asymp. 
Std. 
Error(a) 
Approx. 
T(b) 
Approx. 
Sig. 
Interval by 
Interval 
Pearson's R .029 .106 .304 .762(c)
Ordinal by 
Ordinal 
Spearman Correlation .077 .096 .798 .427(c)
N of Valid Cases 109     
   a  Not assuming the null hypothesis. 
   b  Using the asymptotic standard error assuming the null hypothesis. 
              c  Based on normal approximation. 
   Table 6.16 
 
 
The highest recorded side effects that participants recorded were nausea, 
fatigue, alopecia and other (see Appendix D for descriptions of “other”). These 
side effects were individually correlated with depression scores and again there 
was no statistically significant correlation between the variables. 
 
Question three (3) of the research topic was to see if there was a relationship 
between depressive symptoms, side effects and participant characteristics. 
Firstly, the frequency of depressive symptoms was demonstrated so that the 
researcher could identify the most frequently scored questions on the BDI-II 
and use these in the analysis (See Appendix C for BDI questions). From the 
frequency distributions it was shown that there were 11 out of 21 questions that 
six or more participants recorded a score of one or more on. The questions 
included pessimism, loss of pleasure, guilty feelings, self-dislike, crying, 
agitation, loss of interest, indecisiveness, lack of energy, sleep, irritability, 
appetite, concentration, fatigue and sex.  They were used in the correlation 
analysis with firstly, the patient characteristics, and then the side effects. 
Results illustrated that the variables of pessimism, self-dislike, guilty feelings, 
and loss of interest, indecisiveness and fatigue did rate significant results using 
the Pearson R and Spearman Rank coefficients.  
 
There was a correlation between the type of chemotherapy participants 
received and the variable of pessimism. Pessimism achieved a score of one by 
six participants on the day that they recorded a level of depression. These 
associations showed that participants having Adriamycin, Taxotere and 
Cyclophosphamide (breast cancer) and those that were having Taxol and 
Carboplatin (ovarian) were equally likely to be pessimistic. Another example is 
the relationship between loss if interest and a previous diagnosis of depression 
(Table 6.17). Of the 3 participants of depressed people that reported a history 
of depression also reported a loss of interest.  
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   Correlation of Loss of Interest and Previous Diagnosis for Depression 
 
  
  
 Previous diagnosis for 
depression Total 
  yes no yes 
loss of 
interest 
I have not lost 
interest in other 
people or 
activities 
0 3 3 
  I am less 
interested in 
other people or 
things than 
before 
1 4 5 
  I have lost most 
of my interest in 
other people or 
things 
1 0 1 
  Its hard to get 
interested in 
anything 
1 0 1 
Total 3 7 10 
   Table 6.17 
 
 
 
 
Significance of correlation between loss of interest and previous diagnosis of 
depression 
 
  Value 
Asymp. 
Std. 
Error(a) 
Approx. 
T(b) 
Approx. 
Sig. 
Interval by 
Interval 
Pearson's R -.732 .125 -3.038 .016(c)
Ordinal by 
Ordinal 
Spearman Correlation -.699 .139 -2.761 .025(c)
N of Valid Cases 10     
              a  Not assuming the null hypothesis. 
              b  Using the asymptotic standard error assuming the null hypothesis. 
              c  Based on normal approximation. 
   Table 6.18 
  
 
                
 
 
Other significant results were the correlations between the following: 
  
1. Guilty feelings and age. The respondent that reported that they felt guilt 
most of the time was the youngest participant aged 35. The older 
participants aged 60 and 69, did not report any feelings of guilt. 
2. Self dislike and a previous history of depression. Again, the 3 
participants that recorded a history of depression, also reported self-
dislike. One participant recorded that they had lost confidence in 
themselves and the other 2 reported that they did not like themselves. 
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3. Indecisiveness and type of cancer. Six of the eight breast cancer 
patients found it more difficult than usual to make decisions than usual.  
4.. Fatigue and type of cancer. All of the eight depressed participants with 
breast cancer were more likely to be fatigued yet the participant with 
ovarian cancer rated their fatigued at the highest level and the other 
participants didn’t. 
5. Fatigue and type of chemotherapy. As the type of cancer reflects which 
type of chemotherapy you receive, these results are identical to those 
above. The person with ovarian cancer rated fatigue at its worst, yet 
participants with breast cancer rated this more frequently.  
 
There were also results with a level of significance during the correlation 
analysis of depressive symptoms and side effects. The results showed a 
relationship between the following: 
 
1. Fatigue and lack of concentration. Nine of the ten depressed participants 
recorded some changes to their level of concentration whilst also being 
fatigued as a side effect of the chemotherapy.   
2. Fatigue and loss of pleasure. Of the participants that recorded fatigue as 
a side effect, eight reported that they did not enjoy things as much as 
they used to and one participant said that they get very little pleasure 
from things they used to enjoy. 
3. Fatigue and other side effects. There were a variety of other side effects 
recorded by participants (Appendix D) yet the correlation analysis found 
that half of these recorded some level of fatigue also. 
 
Overall, age and a previous diagnosis of depression were the characteristics 
that had a relationship with the patients’ depressive state. Still significant but 
less so, were type of cancer and type of chemotherapy. Fatigue was the 
primary side effect that participants experienced on the day that they recorded 
a level of depression.    
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CHAPTER 7: DISCUSSION 
 
This report demonstrates that people receiving adjuvant treatment for cancer 
do experience depression and it is more likely to occur in the 5th fortnight of 
their cycle.  This assessment was associated with two results in the analysis, 
looking at a frequency distribution and also by calculating the mean score for 
each fortnight. Depression was more likely in females then males and 
depression was more common in patients receiving treatment for breast 
cancer.  
 
These findings corroborate and extend previous investigations such as, Byar 
et al’s (2006) study on physical and psychological symptoms and their 
relationship to quality of life during chemotherapy. Byar et al (2006) found that 
patients rated a higher degree of depression in the 4th cycle of chemotherapy.  
This would correlate with the 5th fortnight of treatment in the present study 
and would be dependant on whether the patients were receiving the same 
type of treatment. This study, extends Byar et al’s (2006) investigation in that 
it looked beyond breast cancer patients and found that patients rated a more 
frequent rate of depression in the 5th fortnight in other cancer patients also. 
Another study suggestive of a decline in a patient’s psychological status 
through the course of their chemotherapy treatment was by Spagnola et al 
(2003). This study found that quality of life declined from point of diagnosis 
into treatment then improved after treatment into short term and long term 
remissions.   
 
Bottomley et al (1997) established through a literature search that women 
were at greater risk of developing depression which has also been evidenced 
in this current research. This is difficult to validate though as the percentage 
of men and women in the study was not equal.   
 
Initially, the number of side effects that patients experienced was thought to 
have a relationship with depression. Although limited by a relatively small 
sample size, the results from this report indicate that the number of side 
effects experienced by the patients did not necessarily predict depression. In 
contrast to this, the study by Newell et al (1999) did find that the number of 
reported physical symptoms were predictors of elevated levels of anxiety and 
depression. Their findings were that patients that reported four or more 
physical symptoms were more likely to have anxiety or depression than those 
with less than three physical symptoms. In this Masters study, the most 
frequently rated side effects were fatigue and nausea and fatigue was rated 
highest amongst the depressed patients. These findings are consistent with 
results from other studies such as Byar et al (2006) and Tish Knobf et al 
(1990) which also found that fatigue was rated more frequently than any other 
side effect. Tish Knobf (1990) reported fatigue to be common with breast 
cancer therapies, and that ratings of distress and difficulty increased with the 
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number of chemotherapy cycles. Cowley et al (2000) also reported that 
patients’ fatigue levels increased over the course of the six cycles and this 
also had an accumulative mental and physical effect on the patients’ morale 
and motivation.  Byar et al (2006) states in her study, fatigue correlated with 
other physical and psychological symptoms at times during and after 
treatment. Fatigue was significantly predicted by depression, anxiety, pain, 
current tamoxifen use and mastectomy. Higher fatigue was correlated with a 
lower quality of life. The results from this present study illustrated fatigue as a 
significant side effect during their treatment and highlighted a correlation 
between fatigue and some psychological symptoms, more specifically,  loss 
of pleasure and lack of concentration.   
 
Other significant results from this study extend from the correlation analysis 
between depressive symptoms and patient characteristics. Age and a 
previous diagnosis of depression were patient characteristics that denoted a 
relationship with depressive symptoms.  Peveler et al 2002 reported that 
history of depression, marital status, education, stage of disease at diagnosis, 
and type of treatment were patient characteristics that were associated with a 
risk of depression. Molassiotis et al 1996 and Maguire et al 1994 found that 
the type of chemotherapy, such as alkaline and vinca alkaloids (vincristine) 
was influential on a diagnosis of depression. These studies have all found a 
relationship between patient characteristics and depression. The common 
characteristics found between the studies and this present study were a 
previous diagnosis of depression and type of treatment. 
 
The results presented in this study confirm that patients receiving treatment 
for cancer do develop depression and it was also evident that there is a 
relationship between some participant demographic characteristics and 
depressive symptoms. 
 
The conclusive results demonstrate to oncology nurses that depression does 
occur in their patients and that there is a vulnerable point within the treatment 
cycle where it occurs.  The vulnerable point can be defined further in terms of 
specific chemotherapies.  
 
If a patient was receiving treatment for breast cancer and they were receiving 
the chemotherapy cycle Fluorouracil, Epirubicin, Cyclophosphamide (FEC), 
the vulnerable point in this treatment cycle would be between cycle 3 and 4. 
This is because the chemotherapy is received every three weeks for a total of 
6 cycles. This is consistent with findings by Byar.  From the data, if a patient 
was receiving treatment for breast cancer and receiving Adriamycin, taxotere 
and cyclophosphamide, they would also be more vulnerable at the point of 
cycle 3 and 4 as this regime is given in the same fashion as FEC, every 3 
weeks for 6 cycles. 
 
The patient receiving treatment for ovarian cancer received a combination of 
carboplatin and paclitaxel, which is given every 3 weeks for 4 to 6 cycles. The 
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treatment for lymphoma that was received by the patient in this study was 
Rituximab, cyclophosphamide, vincrisine and prednisone (R-CVP) which is 
also given every 21 days for a total of 6-8 cycles. Therefore the vulnerable 
point within the treatment cycle would be the same for all of the different types 
of treatment as they were all given every three weeks.  
 
During the data collection period, the participants were required to complete 
the surveys and return to the researcher as requested. What was unexpected 
was the amount of qualitative data that the participants returned. A number of 
participants wrote letters to the researcher which provided an insight into how 
they were feeling. One participant wrote regularly and the decline in their 
psychological status throughout the course of their treatment was obvious 
and well articulated.   The data (Appendix E) demonstrates the challenges the 
participants faced in undergoing chemotherapy and alludes to the 
vulnerability for depression.  This information has been included to neither 
distract nor enhance the study but to simply provide the reader with tangible 
evidence that patients with cancer are experiencing depression during 
treatment. 
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CHAPTER 8: CONCLUSION 
Although the prevalence of clinically significant depression as identified by the 
BDI-II in this study is relatively low, this investigation demonstrates that patients 
receiving adjuvant chemotherapy are more likely to develop depression between 
cycle 3 and 4. Ten out of twenty-six participants reported some level of 
depression. Of the depressed patients within the research sample, 90% were 
female and 80% of these females were receiving treatment for breast cancer. 
The experience of depression has a negative impact on well being and quality of 
life. Being affected by depression can consequentially affect the course of 
treatment for cancer. Research has revealed that patients with psychological 
morbidity experience a greater number and more intense physical symptoms 
associated with treatment. They also have poorer treatment compliance and 
place a greater strain on the health care system. Early identification and 
treatment of psychological problems has the potential to impact on psychological 
and health outcomes. Early identification and intervention will be easier if nurses 
are able to predict a more vulnerable point within the treatment cycle for their 
patient to develop depression. 
 
The strength of this study is that it is relevant to the health care industry.   From 
the research reviewed in relation to this study, there is still a need to initiate 
psychological screening at an international level. Studies from the United 
Kingdom, United States, China, Australia and Norway, have all indicated a need 
for psychological screening to be undertaken primarily by oncology nurses. The 
Toowoomba oncology clinics used in this research have demonstrated limited 
assessment of the psychological impact of chemotherapy on their patients.   
Knowledge of this research could encourage staff in oncology clinics to 
incorporate a screening technique for assessment of depression in their 
patients. Feedback from one of the oncology clinics involved in the study is that 
they have already implemented a psychological screening tool for their patient 
assessments, and have incorporated the services of a psychologist into their 
service. 
 
The expected outcomes for this project have both patient and health 
professional implications. The results did identify that patients that receive 
adjuvant chemotherapy are experiencing depression within a particular time 
period in their treatment cycle, and this should impact on the nursing care that 
patients receive. Oncology nurses can now be more aware of this vulnerable 
point in the treatment cycle and ensure that they are using assessment 
techniques that will further identify that the patient is experiencing depression.  
Once depression has been identified, professional advice and treatment can be 
organized. This should enhance the patient’s progress through the treatment, 
and also recovery after the treatment. 
 
The limitations of the research are the sample number, self selection bias, self 
reporting bias and missing data. To address the problem of the sample size, the 
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researcher has considered a larger study which would be able to use the data 
from this study to guide future research. Part of this consideration would be to 
have a funded research assistant who would be able to spend more time at the 
oncology clinics to assist the nursing staff to screen potential participants.  They 
would also be available to discuss the study at length with the patients and 
ensure their participation. Another consideration for future studies would be to 
incorporate more oncology clinics if using a regional area, or larger oncology 
clinics if using a metropolitan area.  
 
Another limitation of the study is the missing data due to some of the surveys 
being returned late. To obtain more conclusive and statistically significant results 
the missing data was aided by the transformation used in the SPSS program. To 
avoid this as a problem in the future, the concept of a funded research assistant 
could help to eliminate this by being at the oncology clinics and providing 
reminders to participants on a personal level and having them complete the 
surveys whilst they are there. 
 
An evaluation for the potential use of psychological screening in oncology clinics 
is imperative. This assessment could be incorporated using a standard 
screening test that can be achieved efficiently and incorporated into the 
assessment which already occurs but is limited to physical assessment.  
Oncology nurses experience unique challenging and rewarding relationships in 
a dynamic and multidimensional way. Due to the multifactorial effects of cancer 
and their impact on the psychological wellbeing of patients, the implications for 
oncology nurses to deliver holistic care is imperative. Oncology nurses assess 
and monitor their patients physical conditions, administer medications which are 
toxic to their patients bodies and formulate symptom management strategies to 
overcome the side effects the patients experience from the treatments. These 
caring nurses often witness suffering and death, but survive on the deep and 
ongoing relationships they develop with patients (Rooyen et al 2008). Despite 
the passion and dedication that oncology nurses have to care for their patients,   
from the literature surrounding this topic it became clear that there was still a 
lack of assessment or recognition of psychological issues for these patients.  
Perhaps the need and intention of the oncology nurses to look after their 
patients holistically is there yet they lack the support or tools to be able to 
manage it. 
 
This study, by demonstrating the presence of depression in patients receiving 
adjuvant chemotherapy must foster awareness for the potential psychological 
side effects of treatment. Emotional support, appropriate management of 
chemotherapy side effects, ongoing assessment of individual needs and open 
communication is imperative to enhancing continuity and quality of care 
delivered to cancer patients. 
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APPENDIX  B 
DEPRESSION IN PATIENTS WITH CANCER RECEIVING ADJUVANT 
CHEMOTHERAPY 
 
Participant Information Sheet 
 
Principal Researcher: Kate Beyer  
  Registered Nurse 
  Bachelor of Nursing (CQU) 
  Enrolled Masters of Health (USQ) 
  Phone: (07) 46362146 
 
This information sheet is 3 pages long. Please make sure that you have all the 
pages. 
 
1. Your Consent 
 
This participant information sheet contains detailed information about the 
research project. Its purpose is to explain to you as openly and clearly as 
possible, all the procedures involved in this project before you decide whether or 
not you wish to participate. 
 
Please read the information carefully. Feel free to ask any questions about any 
information in the document. You may also wish to discuss this project with a 
relative, friend or health care provider. Feel free to do this. 
 
Once you understand what the project is about and if you agree to take part in it, 
you will be asked to sign a Consent Form. By signing the Consent Form, you 
indicate that you understand the information and that you agree to participate in 
the project. 
 
You will be given a copy of the Participant Information Sheet and the Consent 
Form to keep as a record. 
 
2. Purpose and Background 
 
The purpose of this project is to establish the incidence of depression in patients 
receiving adjuvant chemotherapy and establish if there is a vulnerable point in 
the chemotherapy treatment cycle in which patients develop depression. 
 
Previous experience has revealed that depression does occur in patients that 
receive adjuvant chemotherapy, yet there is little evidence if there is a point in 
the treatment process when patients are most vulnerable. 
 
A total of 30-40 people will participate in the project. 
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You are being invited to participate in this project because the research is being 
conducted in conjunction with Toowoomba Health Service District and St. 
Andrews Hospital, and you meet the criteria to be included in the study. 
 
 
                       
  3.    Procedure 
Participation in this project will involve completing a self-rating questionnaire, 
called the Beck Depression Inventory. The questionnaire contains 21 questions 
and should take approximately 10 minutes to complete. You will be asked to 
complete this questionnaire at two weekly intervals during the course of your 
treatment. You will be provided with copies of the questionnaire at the beginning 
of your participation, and asked to mail them to the Principal Researcher in 
stamped, self addressed envelopes. If the form is not received, the principal 
researcher will phone or email you as a friendly reminder. You will also be asked 
to complete a form that requires providing some demographic information for the 
researcher, and to complete a tick sheet regarding side effects of chemotherapy 
that you may experience. 
 
4.  Possible Benefits 
 
Possible benefits to yourself may include a self realisation of how you are feeling 
during your treatment and therefore, if you are feeling depressed you may seek 
advice when normally you wouldn’t have. Other benefits of the study will be for 
future patients with cancer. By identifying a vulnerable point in a patient’s 
treatment cycle of chemotherapy will be helpful to the nursing staff and other 
health care providers to be more aware of and diagnose and address any 
adverse feelings a patient may be experiencing. We cannot guarantee or 
promise that you will receive any benefit from taking part in this project. 
 
5. Possible risks 
 
Possible risks, side effects and discomforts from completing the questionnaire 
are minimal. 
There may be additional unforseen or unknown risks. The principal researcher 
does wish to advise you though, that participation can be ended or suspended at 
any time for any reason during the study. 
 
6. Privacy, confidentiality and disclosure of information 
 
The responses that I receive from you, the participant, is known as data and will 
be stored as a hard copy in a locked filing cabinet. It will also be stored 
electronically under password protected data files on a password protected 
computer. The data is not identifiable to anyone and only the principal 
researcher will have access to it. The data will be stored for a period of 7 years 
and at the end of this term be disposed of as confidential waste. 
 
7.  New information arising during the project 
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During the research project, new information about the risks and benefits of the 
project may become known to researchers. If this occurs, you will be told about 
this new information. This new information may mean that you can no longer 
participate in this research. If this occurs, the principal researcher will stop your  
participation. In all cases, you will be offered all available care to suit your needs 
and medical condition. 
 
 
8. Further Information or any problems 
 
If you require any further information or if you have any problems concerning 
this project, please contact the principal researcher, Kate Beyer, on (07) 
46362146 or 0409875300. 
 
9. Other Issues 
 
This project will be carried out according to the National Statement on Ethical 
Conduct in Research Involving Humans (June 1999) produced by the National 
Health and Medical Research Council of Australia. The ethical aspects of this 
research have been approved by the Toowoomba Health Service District 
Human Research Ethics Committee and University of Southern Queensland 
Ethics Committee.  
If you have any complaints or concerns about the conduct of this research, 
please contact the Chair-Human Ethics Committee, Toowoomba Health District 
on (07) 46166190. If you have concerns about your participation in this research 
conflicting with aspects of your cultural practice or belief system, in the first 
instance please inform the Principal Researcher, Kate Beyer on (07) 46362146 
or 0409875300. 
 
10.   Participation is voluntary 
 
Participation in any research project is voluntary. If you do not wish to take part 
you are not obliged to. If you decide to take part and later change your mind, 
you are free to withdraw from the project at any stage. 
 
11.  Reimbursement for costs 
 
You will not be reimbursed for your participation in this project. 
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APPENDIX  C 
The Beck Depression Inventory 
 
Read each question carefully, and circle the one statement in each that 
best describes the way you have been feeling during the past two weeks, 
including today.  
 
 
1. Sadness 
0    I do not feel sad. 
1    I feel sad much of the time 
2   I am sad all of the time. 
3    I am so sad or unhappy that I can't stand it. 
  
2. Pessimism 
0   I am not discouraged about my future. 
1   I feel more discouraged about my future than I used to be. 
2   I do not expect things to work out for me. 
3   I feel my fortune is hopeless and will get only worse. 
 
3. Past Failure 
0   I do not feel like a failure. 
1   I have failed more than I should have. 
2   As I look back I see a lot of failures. 
3   I feel I am a total failure as a person. 
 
4. Loss of Pleasure 
0   I get as much pleasure as I ever did from the things I enjoy. 
1   I don't enjoy things as much as I used to. 
2   I get very little pleasure from the things I used to enjoy. 
3   I can't get any pleasure from the things I used to enjoy. 
 
5. Guilty Feelings 
0   I don't feel particularly guilty. 
1   I feel guilty over many things I have done or should have done. 
2   I feel quite guilty most of the time. 
3   I feel guilty most of the time. 
 
6. Punishment Feelings 
0   I don't feel I am being punished. 
1   I feel I may be punished. 
2   I expect tot be punished. 
3   I feel I am being punished. 
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7. Self-Dislike 
0   I feel the same about myself as ever. 
1   I have lost confidence in myself. 
2   I am disappointed in myself. 
3   I dislike myself. 
 
8. Self-Criticisms 
0   I don't criticize or blame myself more than usual. 
1   I am more critical of myself than I used to be. 
2   I criticize myself for all of my faults. 
3   I blame myself for everything bad that happens. 
  
9. Suicidal Thoughts or Wishes 
0   I don't have any thoughts of killing myself. 
1   I have thoughts of killing myself, but I would not carry them out. 
2   I would like to kill myself. 
3   I would kill myself if I had the chance. 
  
10. Crying 
0   I don't cry anymore than I used to. 
1   I cry more than I used to. 
2   I cry over every little thing. 
3   I feel like crying, but I can't. 
  
11. Agitation 
0   I am no more restless or wound up man usual. 
1   I feel more restless or wound up than usual. 
2   I am so restless or agitated that it's hard to stay still. 
3   I am so restless that I have to keep moving or doing something. 
 
12. Loss of Interest 
0   I have not lost interest in other people or activities. 
1   I am less interested in other people or things than before. 
2   I have lost most of my interest in other people or things. 
3   It's hard to get interested in anything. 
 
13. Indecisiveness 
0   I make decisions about as well as ever. 
1   I find it more difficult to make decisions than usual. 
2   I have much greater difficulty in making decisions than usual. 
3   I have trouble making any decisions. 
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14. Worthlessness 
0   I do not feel I am worthless. 
1   I don't consider myself as worthwhile and useful as I used to. 
2   I feel more worthless as compared to other people. 
3   I feel utterly worthless. 
 
15. Loss of Energy 
0   I have as much energy as ever. 
1   I have less energy than I used to have. 
2   I don't have enough energy to do very much. 
3   I don't have enough energy to do anything. 
 
16. Changes in Sleeping Pattern  
0   I have not experienced any change in my sleeping pattern. 
1   I  sleep somewhat more/less than usual, 
2   I sleep a lot more/less than usual. 
3   I sleep most of the day. 
     I wake up 1-2 hours early and can't get back to sleep. 
 
17. Irritability 
0   I am no more irritable than usual. 
1   I am more irritable than usual. 
2   I am much more irritable than usual. 
3   I am irritable all the time. 
 
18. Changes in Appetite 
0   I have not experienced any change in my appetite. 
1   My appetite is somewhat greater/lesser than usual. 
2   My appetite is much greater/lesser than usual. 
3   I crave food all the time or I have no appetite at all. 
 
19. Concentration Difficulty 
0   I can concentrate as well as ever. 
1   I can't concentrate as well as usual. 
2   It's hard to keep my mind on anything for very long. 
3   I find I can't concentrate on anything. 
 
20. Tiredness or Fatigue 
0   I am no more tired or fatigued than usual. 
1   I get more tired or fatigued more easily than usual. 
2   I am too tired or fatigued to do a lot of the things I used to do. 
3   I am too tired or fatigued to do most of the things I used to do. 
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21. Loss of Interest in Sex 
0   I have not noticed any recent change in my interest in sex. 
1   I am less interested in sex than I used to be. 
2   I am much less interested in sex now. 
3   I have lost interest in sex completely. 
 
 
 
Scoring   
0-13    Normal   
14-19  Mild   
20-28  Moderate 
29-63  Severe   
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APPENDIX D 
 
Samples of “other” side effects 
 
Aching legs in feet 
Aches in jaw 
Headaches 
Sore veins 
Extremely sore veins and bruising from the cannulation 
 
Sore joints for a few days 
Sore gums for a few days 
Dizziness (gradually wears off after a week or so) 
Dizziness – loss of balance 
Gums sore at times 
 
Painful veins in forearm from chemo 
Night sweats, hot flushes and changes sleep patterns 
A pounding headache that lasted about 15 hours 
Night sweats – almost hourly throughout the night for 7-10days after 
chemo, some hot flushes through day 
No period 
Temp 38.2 – admitted to hospital 
Infection in PICC line 
UTI 
Thrombosis in left upper and lower arm due to Portacath 
 
Some swelling of fingers on day of chemo until next day 
Heaviness in limbs for a couple of days 
Heaviness in limbs and swelling in fingers and ankles for the first 2 days 
after chemo 
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Head cold for a few weeks and cough and runny nose making me tired 
and getting less sleep. I pulled a muscle in rib cage from coughing which 
is painful.  
Aching in legs 
Developed URTI – on antibiotics 
 
Foul taste in mouth 
Awful taste in mouth, everything is very salty. It used to be metallic taste 
but changed to salty. I found the more treatments I had the awful taste 
was worse and lasted longer. 
 
Terrible metallic taste in my mouth 
Terrible taste in my mouth all the time for one week after my first 
treatment 
 
Dizziness and off balance from anti-depressants 
 
Red and burning face after chemo 
Pain up arm (right) this is the arm I have chemo in 
 
I have a blood clot in right leg caused by high dosage of chemo. I am 
having ½ strength chemo at present 
I am still having injections for my blood clot but my leg is improving 
Swollen legs with fluid and pain in joints 
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